• ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/ gem)

  McNamara, Mairead G; Timmins, H.; Osborne, A.; Cox, R.; Wasan, H. S.; Corrie, P.; Gillmore, R.; Sivakumar, S.; Ma, Y. T.; Faluyi, O. O.; et al. (2023)
• The FOxTROT platform: Clinical trials and exploratory research for personalization of neoadjuvant (NA) therapy in locally advanced colon cancer (LACC)-ISRCTN83842641

  Williams, C.; White, M.; Platt, J. R.; Glasbey, J.; Bailey, L.; Magill, L.; Wheatstone, P.; Cooper, L.; Beggs, A. D.; Braun, Michael S; et al. (2023)
• 

  Influence of the manufacturing process on the corrosion and mechanical behavior of esophageal stents

  Alferi, D.; Fojt, J.; Kristianova, E.; Edwards, D. W.; Laasch, Hans-Ulrich; Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic (2023)

  Esophageal nitinol stents are an established method for treating swallowing difficulties caused by obstructing cancer. This raesearch investigates the influence of different qualities of raw metal alloys in combination with production technology on corrosion resistance in standardized simulated gastric fluid (SGF). Four different international stent manufacturers produced samples of their standard stents from nitinol sourced from three different alloy manufacturers. The stents were subjected to a 6-week immersion in SGF. During the immersion, the surface was studied at specified intervals using microscopy. The surface of the samples was also studied by X-ray Photoelectron Spectroscopy and after immersion the released ions were analyzed. Results demonstrated that both raw material and certain steps in the manufacturing process negatively affect corrosion resistance. Analysis of the SGF showed that the amount of nickel released is proportional to the degree of corrosion attack. Finally, current accepted standard test methods are inadequate for assessing susceptibility to corrosion by gastric acid and should take the low pH of the implanted environment into account. Conversely, certain measures in the manufacturing process are able to reduce the impact of the base material on corrosion susceptibility.
• REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

  Seckl, M.; Ghorani, E.; Quartagno, M.; Blackhall, Fiona H; Gilbert, D. C.; O'Brien, M. E. R.; Ottensmeier, C. H. H.; Pizzo, E.; Spicer, J. F.; Williams, A.; et al. (2023)
• A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)

  Besse, B.; Paz-Ares, L. G.; Peters, S.; Cappuzzo, F.; Reck, M.; Calles, A.; Califano, Raffaele; Lopez-Vilarino, J. A.; Veramendi, S.; Kahatt, C. M.; et al. (2023)
• A phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutation

  Lindsay, Colin R; Veluswamy, R.; Castro, G.; Tan, D. S. W.; Caparica, R.; Glaser, S.; Malhotra, S.; Boran, A.; Felip, E.; The Christie Hospital NHS Foundation Trust, Manchester (2023)
• Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients (EORTC-1901: PRIMALung)

  Levy, A.; Berghmans, T.; Andratschke, N.; Leonetti, G.; Koller, M.; Faivre-Finn, Corinne; Gustave Roussy, Villejuif, France (2023)
• Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)

  Okines, A. F. C.; Braybrooke, J.; MacPherson, I. R.; Sutherland, S.; Howell, Sacha J; Wheatley, D.; Waters, S.; Roylance, R.; Baird, R. D.; Oikonomidou, O.; et al. (2023)
• Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design

  Van Akkooi, A. C. J.; Hauschild, A.; Long, G. V.; Mandalà, M.; Kicinski, M.; Govaerts, A. S.; Klauck, I.; Ouali, M.; Lorigan, Paul C; Eggermont, A. M.; et al. (2023)
• Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)

  Paz-Ares, L. G.; Felip, E.; Ahn, M. J.; Blackhall, Fiona H; Borghaei, H.; Cho, B. C.; Johnson, M. L.; Ramalingam, S. S.; Reck, M.; Zhang, A.; et al. (2023)
• Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma

  Grover, P.; Li, I.; Kuijpers, A.; Kreidieh, F. Y.; Williamson, A.; Amaral, T. M. S.; Dimitriou, F.; Placzke, J.; Olino, K.; Vitale, M. G.; et al. (2023)
• A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma

  Patel, M. R.; Ahearne, M.; Linton, Kim M; Fox, C.; Lewis, D. J.; Higgins, M.; Schwartz, B. E.; Beer, P. A.; Tees, M. T.; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL (2023)
• UK cancer healthcare professionals collaborating with colleagues in low- and middleincome counties: Mapping the extent and nature of partnerships

  Diprose, K.; Lewis, P.; Young, A.; Sirohi, B.; Ranasinghe, N.; Mutebi, M. C.; Gyawali, B.; Lodge, M.; Sullivan, R.; Cowan, Richard; et al. (2023)
• Tumour mutational burden as a predictive and prognostic biomarker in locally advanced and recurrent/metastatic adenoid cystic carcinoma

  Patel, Karan; Rack, Samuel; Mistry, H.; Heathcote, Emily; Betts, G.; Harrington, K. J.; Metcalf, Robert; The Christie Hospital NHS Foundation Trust, Manchester (2023)
• Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC)

  Skoulidis, F.; De Langen, A.; Paz-Ares, L. G.; Mountzios, G. S.; Curioni-Fontecedro, A.; Couraud, S.; Janssens, A.; Rocco, D.; Ohashi, K.; Vincent, M. D.; et al. (2023)
• Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion- positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1

  Lin, J. J.; Drilon, A. E.; Cho, B. C.; Felip, E.; De Langen, A.; Yang, N.; Kim, S. W.; Lu, S.; Kao, S. C. H.; Velcheti, V.; et al. (2023)
• Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose

  Minchom, A. R.; Krebs, Matthew G; Cho, B. C.; Lee, S. H.; Leighl, N. B.; O'Neil, B.; Sabari, J. K.; Kudgus-Lokken, R.; Alhadab, A.; Haddish-Berhane, N.; et al. (2023)
• Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis

  Champiat, S.; Boyer, M. J.; Govindan, R.; Paz-Ares, L. G.; Owonikoko, T. K.; Borghaei, H.; Izumi, H.; Steeghs, N.; Blackhall, Fiona H; Terbuch, A.; et al. (2023)
• Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial

  Karimi, Y.; Ghesquieres, H.; Jurczak, W.; Cheah, C.; Clausen, M.; Lugtenburg, P.; Cunningham, D.; Do, Y. R.; Lewis, D. J.; Gasiorowski, R.; et al. (2023)
• Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data

  Falchi, L.; Clausen, M.; Offner, F.; De Vos, S.; Brody, J.; Linton, Kim M; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; et al. (2023)

View more